7月8日,先声药业乐德奇拜单抗注射液的上市申请获得NMPA受理,为康诺亚之后第2款国产IL-4R抗体。图源:NMPA官网乐德奇拜单抗是一种针对IL-4Rα的全人源单克隆抗体,它通过阻断IL-4和IL-13这两种关键的炎症细胞因子来治疗中重度哮喘。这种药物的优势在于其精准靶向2型炎症通路,这在哮喘的发病机制中起着核心作用。乐德奇拜单抗由康乃德研发,2023年11月21日,先声药业以1.5亿元人民币...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.